{"nctId":"NCT00666458","briefTitle":"18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)","startDateStruct":{"date":"2008-04"},"conditions":["Type 2 Diabetes"],"count":822,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: saxagliptin"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: sitagliptin"]}],"interventions":[{"name":"saxagliptin","otherNames":["Onglyza"]},{"name":"sitagliptin","otherNames":["Januvia"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes\n* Treatment with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks\n\nExclusion Criteria:\n\n* Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar non-ketotic coma\n* Insulin therapy within one year\n* Previous treatment with DPP-4 inhibitor","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hemoglobin A1c (HbA1c) Change From Baseline to Week 18","description":"Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus sitagliptin added on to metformin at Week 18 (Per Protocol Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 18 value minus the baseline value.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.68","spread":"0.052"},{"groupId":"OG001","value":"7.69","spread":"0.047"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.16","spread":"0.052"},{"groupId":"OG001","value":"7.07","spread":"0.051"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.52","spread":"0.039"},{"groupId":"OG001","value":"-0.62","spread":"0.038"}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients Achieving Therapeutic Glycaemic Response Defined as HbA1c <= 6.5% at Week 18","description":"Proportion of Patients Achieving Therapeutic Glycaemic Response Defined as HbA1c \\<= 6.5% at Week 18 (Full Analysis Set)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.3","spread":null},{"groupId":"OG001","value":"29.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose Change From Baseline to Week 18 (mg/dL)","description":"Adjusted mean change from baseline in Fasting Plasma Glucose achieved with saxagliptin added on to metformin versus sitagliptin added on to metformin at Week 18 (Full Analysis Set). Fasting Plasma Glucose is a continuous measure, the change from baseline for each participant is calculated as the Week 18 (LOCF) value minus the baseline value.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"159.67","spread":"2.280"},{"groupId":"OG001","value":"160.22","spread":"2.192"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149.04","spread":"1.991"},{"groupId":"OG001","value":"143.94","spread":"1.864"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.75","spread":"1.455"},{"groupId":"OG001","value":"-16.16","spread":"1.464"}]}]}]},{"type":"SECONDARY","title":"Fasting Plasma Glucose Change From Baseline to Week 18 (mmol/L)","description":"Adjusted mean change from baseline in Fasting Plasma Glucose achieved with saxagliptin added on to metformin versus sitagliptin added on to metformin at Week 18 (Full Analysis Set). Fasting Plasma Glucose is a continuous measure, the change from baseline for each participant is calculated as the Week 18 (LOCF) value minus the baseline value.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.86","spread":"0.127"},{"groupId":"OG001","value":"8.89","spread":"0.122"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.27","spread":"0.111"},{"groupId":"OG001","value":"7.99","spread":"0.103"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.60","spread":"0.081"},{"groupId":"OG001","value":"-0.90","spread":"0.081"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":403},"commonTop":["Urinary Tract Infection","Influenza"]}}}